Search results for "type 1"

showing 10 items of 540 documents

Elevated protein carbonyl and HIF-1α levels in eyes with proliferative diabetic retinopathy.

2013

Purpose: To evaluate the role of protein carbonyls and hypoxia inducible factor-1a (HIF-1a) in diabetic eyes with proliferative diabetic retinopathy (PDR). Methods: Prospective consecutive controlled observational study was performed. Vitreous samples were collected at the start of the 3-ppp vitrectomy. Protein carbonylation analysis was performed by Western blotting with antibody against 2,4-Dinitrophenol (anti-DNP), following derivatization of protein carbonyls with 2,4 Dinitrophenylhydrazine (DNHP). Protein carbonylation was quantified by scanning densitometry analysis and relativized to the total amount of protein into the ponceau staining of membranes. Vitreous HIF-1 a was determined w…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresmedicine.medical_treatmentProtein CarbonylationBlotting WesternVitrectomyEnzyme-Linked Immunosorbent Assaymedicine.disease_causePathogenesisProtein Carbonylationchemistry.chemical_compoundOphthalmologyVitrectomymedicineHumansProspective StudiesMacular holeAgedGlycated HemoglobinDiabetic Retinopathybusiness.industryRetinal detachmentGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseHypoxia-Inducible Factor 1 alpha Subuniteye diseasesSurgeryVascular endothelial growth factorVitreous BodyOphthalmologyOxidative StressDiabetes Mellitus Type 1chemistryDiabetes Mellitus Type 2Femalesense organsbusinessOxidative stressActa ophthalmologica
researchProduct

One

2019

Neurofibromatosis type 1 (NF1) is an autosomal dominant disease with complete penetrance but high variable expressivity. NF1 is caused by loss-of-function mutations in the NF1 gene, a negative regulator of the RAS-MAPK pathway. The NF1 gene has one of the highest mutation rates in human disorders, which may explain the outbreak of independent de novo variants in the same family. Here, we report the co-occurrence of pathogenic variants in the NF1 and SPRED1 genes in six families with NF1 and Legius syndrome, using next-generation sequencing. In five of these families, we observed the co-occurrence of two independent NF1 variants. All NF1 variants were classified as pathogenic, according to t…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesSPRED1Neurofibromatosis 1Neurofibromin 1AdolescentCafe-au-Lait Spotsneurofibromatosis type 1eye diseasesArticlenervous system diseasesPedigreeLegius syndromePhenotypeNF1MutationHumansFemalede novo variantChildneoplasmsAdaptor Proteins Signal TransducingGenes
researchProduct

Study of pituitary secretion in relation to retinopathy in patients with juvenile diabetes mellitus.

1981

Fifteen juvenile diabetic patients with normal eye fundus, 6 with non proliferative retinopathy, 5 with proliferative retinopathy and 5 healthy control subjects were studied in order to investigate pituitary function in relation to diabetic retinopathy. ACTH values at 08(00) and 18(00), hPRL and TSh secretion in response to 200 microgram TRH i.v., and GH secretion in response to 500 mg oral L-dopa were evaluated. In all diabetic subjects, 08(00) ACTH levels were lower than in controls. Basal hPRL, TSH and GH values of the diabetics did not differ from those of the controls. No significant differences were found in hPRL levels in response to TRH, whereas significantly lower TSH responses wer…

AdultMaleendocrine systemPituitary glandmedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismThyrotropin-releasing hormoneThyrotropinAdrenocorticotropic hormoneLevodopaEndocrinologyAdrenocorticotropic HormoneInternal medicineDiabetes mellitusInternal MedicineMedicineHumansThyrotropin-Releasing HormoneDiabetic Retinopathybusiness.industryGeneral MedicineDiabetic retinopathymedicine.diseaseGrowth hormone secretionProlactinProlactinKineticsmedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 1Growth HormonePituitary GlandFemalebusinesshormones hormone substitutes and hormone antagonistsRetinopathyActa diabetologica latina
researchProduct

Teprotumumab for Thyroid-Associated Ophthalmopathy

2017

Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy.We conducted a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopathy. A total of 88 patients were randomly assigned to r…

AdultMalemedicine.medical_specialty030209 endocrinology & metabolismDiseaseAdult; Aged; Antibodies Monoclonal; Diabetes Complications; Double-Blind Method; Exophthalmos; Female; Graves Ophthalmopathy; Humans; Hyperglycemia; Immunologic Factors; Insulin-Like Growth Factor I; Intention to Treat Analysis; Logistic Models; Male; Middle Aged; Quality of LifeAntibodies Monoclonal HumanizedPlaceboAntibodiesReceptor IGF Type 1law.inventionDiabetes ComplicationsGraves' ophthalmopathy03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicineMonoclonalmedicineClinical endpointExophthalmosHumansImmunologic FactorsInsulin-Like Growth Factor IAgedIntention-to-treat analysisTeprotumumabbusiness.industryAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseIntention to Treat AnalysisGraves OphthalmopathyLogistic ModelsHyperglycemiaMonoclonalImmunologyQuality of Life030221 ophthalmology & optometryFemalebusinessmedicine.drugNew England Journal of Medicine
researchProduct

Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level

2014

Patients with diabetes caused by single-gene mutations generally exhibit an altered course of diabetes. Those with mutations of the glucokinase gene (GCK-MODY) show good metabolic control and low risk of cardiovascular complications despite paradoxically lowered high-density lipoprotein (HDL) cholesterol levels. In order to investigate the matter, we analyzed the composition of low-density lipoprotein (LDL) and HDL subpopulations in such individuals. The LipoPrint(©) system (Quantimetrix, USA) based on non-denaturing, linear polyacrylamide gel electrophoresis was used to separate and measure LDL and HDL subclasses in fresh-frozen serum samples from patients with mutations of glucokinase or …

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismBiologyLipid subpopulationsYoung Adultchemistry.chemical_compoundEndocrinologyMonogenic diabetesInternal medicineDiabetes mellitusGlucokinasemedicineInternal MedicineHumansHepatocyte Nuclear Factor 1-alphaChildType 1 diabetesmedicine.diagnostic_testCholesterolGlucokinaseCholesterol HDLCase-control studynutritional and metabolic diseasesCholesterol LDLGeneral Medicinemedicine.diseaseLipoproteins LDLDiabetes Mellitus Type 1EndocrinologychemistryCase-Control StudiesMetabolic control analysisMODYOriginal ArticleFemalelipids (amino acids peptides and proteins)Lipoproteins HDLLipid profileLipoproteinActa Diabetologica
researchProduct

Insulin-dependent diabetes mellitus and glycosaminoglycans.

1995

The influence of diabetic nephropathy on urinary glycosaminoglycan distribution was assessed in 96 patients with insulin-dependent diabetes mellitus (IDDM, 49 female, age: 16 - 64 yrs, median 35; duration of IDDM: 0 - 43 yrs, median 13 yrs) in comparison to 103 healthy controls (57 female, 17 - 82 yrs, median 40 yrs). Glycosaminoglycan concentration of 24 h urine samples was determined by means of precipitation with cethylpyridinium chloride and potassium acetate in ethanol followed by a colorimetric test with carbazole. A marked difference (p = 0.0008) in urinary glycosaminoglycan excretion between patients (19.0, 12.4, 35.6 mg/24 h, median, 25th, 75th percentile) and controls (15.8, 10.4,…

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismUrinary systemClinical BiochemistryBiochemistryNephropathyDiabetic nephropathyExcretionGlycosaminoglycanEndocrinologyDiabetes mellitusInternal medicinemedicineHumansDiabetic NephropathiesAgedGlycosaminoglycansAged 80 and overDiabetic Retinopathybusiness.industryBiochemistry (medical)General MedicineMiddle Agedmedicine.diseaseUrinary glycosaminoglycan excretionEndocrinologyDiabetes Mellitus Type 1FemalebusinessRetinopathyHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
researchProduct

Prevalence of residual B-cell function related to age at onset and genetic profile in newly diagnosed type I diabetics.

1987

Patients with type I (insulin-dependent) diabetes mellitus maintain B-cell function for a varying period of time after onset. This is commonly held to account for post-initial remission. To estimate residual B-cell function we measured plasma and 24-h urinary C-peptide in 68 type I diabetic patients (age range 4-35 years, within 10-180 days of the onset of symptoms, typed for HLA-A, -B, -C and DR loci. A positive correlation (r = 0.26; p less than 0.05) was found between urinary C-peptide levels and the age of the patient. The analysis of variance of urinary C-peptide values on the basis of the presence or absence of DR3 and DR4 antigens revealed that the DR3-positive patients had reduced e…

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismUrinary systemLate onsetGastroenterologyExcretionchemistry.chemical_compoundIslets of LangerhansEndocrinologyAntigenInternal medicineDiabetes mellitusInternal MedicinemedicineHumansChildB cellC-PeptideC-peptidebusiness.industryAge FactorsGeneral MedicineHLA-DR Antigensmedicine.diseaseEndocrinologymedicine.anatomical_structureDiabetes Mellitus Type 1chemistryChild PreschoolFemaleAnalysis of variancebusinessActa diabetologica latina
researchProduct

Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxida…

2008

Background and objective: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Recent studies suggest there is an angiotensin II-dependent increase in adhesion molecules and oxidative stress parameters during AF. These alterations appear to contribute to inflammatory and prothrombotic changes in the atrial endocardium (‘endocardial remodelling’), suggesting that patients with increased levels of these factors might be at risk of thromboembolic events. The purpose of the CREATIVE-AF (Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients with Persistent Atrial Fibrillation) trial is to prove the principle concept that blockade of angiotensin II type 1 r…

AdultMalemedicine.medical_specialtyAdolescentEndpoint DeterminationTetrazolesmedicine.disease_causeYoung AdultIrbesartanVon Willebrand factorDouble-Blind MethodInternal medicineAtrial FibrillationmedicineHumansPharmacology (medical)Cell adhesionAgedCross-Over StudiesbiologyCell adhesion moleculebusiness.industryPatient SelectionBiphenyl CompoundsAtrial fibrillationGeneral MedicineIrbesartanMiddle Agedmedicine.diseaseAngiotensin IICrossover studyOxidative StressData Interpretation StatisticalSample SizeCardiologybiology.proteinFemalebusinessAngiotensin II Type 1 Receptor BlockersCell Adhesion MoleculesOxidative stressBiomarkersmedicine.drugClinical drug investigation
researchProduct

Selenium, zinc and copper in plasma of patients with type 1 diabetes mellitus in different metabolic control states

1998

The Studies of selenium (Se), zinc (Zn) and copper (Cu) levels in diabetic patients have led to contradictory findings as the possible relationship between the degree of diabetic control and the changes in mineral contents. In the present study the plasma Cu, Se, and Zn contents of diabetic patients and healthy people were measured and the relationship between these contents and diabetic metabolic control, as determined by glycosylated hemoglobin (HbA1c), was studied. The mean plasma Se content in diabetic patients was significantly lower than in controls (p < 0.01) and a negative correlation between the plasma contents of Se and HbA1c was found. No statistically significant differences in …

AdultMalemedicine.medical_specialtyAdolescentchemistry.chemical_elementZincBiochemistryInorganic ChemistrySeleniumInternal medicineDiabetes mellitusBlood plasmamedicineHumansChildType 1 diabetesChemistryMiddle Agedmedicine.diseasePathophysiologyZincDiabetes Mellitus Type 1EndocrinologyMetabolic control analysisMolecular MedicineFemaleHemoglobinCopperSelenium
researchProduct

Immunoregulatory T-lymphocyte subset deficiency in newly diagnosed Type 1 (insulin-dependent) diabetes mellitus

1984

Humoral and cell-mediated disorders in Type 1 (insulin-dependent) diabetes suggest that an imbalance of immunoregulatory T-cell subsets exists. In 23 newly diagnosed (onset less than 3 months) and 21 long-standing Type 1 diabetic patients, T lymphocyte subsets were analyzed using monoclonal antibodies (OKT3, OKT4, OKT8, OKM1). The newly diagnosed patients showed a reduction with a significant difference from healthy controls in total T cells (OKT3+: 58.1 +/- 8.5% versus 70.7 +/- 8.0%), helper/inducer cells (OKT4+: 33.8 +/- 7.0% versus 47.1 +/- 8.3%), suppressor/cytotoxic cells (OKT8+: 18.5 +/- 7.3% versus 32 +/- 6.8%) and monocytes (OKM1+: 11.5 +/- 3.8% versus 19.9 +/- 5.2%) (p less than 0.…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classT-LymphocytesEndocrinology Diabetes and Metabolismchemical and pharmacologic phenomenaNewly diagnosedBiologyMonoclonal antibodymedicine.disease_causeT-Lymphocytes RegulatoryMonocytesAutoimmunityPathogenesisIslets of LangerhansLeukocyte CountDiabetes mellitusInternal medicineInternal MedicinemedicineHumansCytotoxic T cellChildType 1 diabetesImmunologic Deficiency SyndromesAntibodies MonoclonalT-Lymphocytes Helper-InducerT lymphocytemedicine.diseaseDiabetes Mellitus Type 1EndocrinologyFemaleT-Lymphocytes CytotoxicDiabetologia
researchProduct